Starting a statin early after a diabetes diagnosis tracked with 15% less dementia

A large Danish study presented at a major European cardiology meeting found that people who started a cholesterol-lowering statin soon after being diagnosed with type 2 diabetes were less likely to be diagnosed with dementia over the following decade than those who never started one. The researchers behind the work are careful to note that the study shows only an association, not proof that statins protect the brain. Because statins are cheap and already widely prescribed for heart health, the researchers say the pattern is still worth attention from doctors and patients weighing when to start treatment.

A Nationwide Danish Registry Followed 132,585 New Diabetes Patients

The findings come from a nationwide analysis of Danish health registers led by Dr. Tummas Ternhamar of Copenhagen University Hospital, presented at the European Society of Cardiology’s ESC Congress 2026 and published in the journal The Lancet Regional Health – Europe. Researchers identified 132,585 people in Denmark who had never taken a statin before being diagnosed with type 2 diabetes between 2006 and 2019. Medical records were then searched for any diagnosis of dementia, with follow-up continuing through the end of 2021. The work was presented on August 30 during a session on diabetes and heart disease at ESC Congress 2026 in Munich, Germany, and was funded in part by the Danish Cardiovascular Academy, the Novo Nordisk Foundation and the Danish Heart Foundation.

Early Statin Users Had a 15 Percent Lower Relative Risk Over a Decade

Over a median follow-up of 7.1 years, 2.7% of the entire study population went on to develop dementia. Compared with people who never started a statin within five years of their diabetes diagnosis, those who started one within the first year had a 15% lower relative risk of dementia over 10 years. People who started later, between one and five years after diagnosis, had a 10% lower relative risk. The pattern held similarly for women and men, according to the presentation.

A Clone-Censor-Weight Design Tries to Emulate a Clinical Trial

Because no one randomly assigned patients to start or skip statins, the team used a statistical approach called a clone-censor-weight design, which is built to mimic the structure of a randomized trial using observational data. Ternhamar said the method was chosen specifically “to emulate a randomised trial and reduce some of the bias associated with observational studies,” such as the possibility that healthier patients are simply more likely to be prescribed and to keep taking a statin in the first place. That kind of “healthy-adherer” pattern is a common problem in drug studies built from registry data rather than a controlled trial: people who fill prescriptions regularly also tend to see doctors more often, follow other medical advice more closely and generally have better-monitored health overall, any of which could independently lower dementia risk regardless of the statin itself. The clone-censor-weight method does not eliminate that possibility, but it is designed to reduce its influence on the comparison.

High LDL Cholesterol Links Diabetes to Cognitive Decline

The rationale for the study traces back to a 2024 report from the Lancet’s standing Commission on dementia that estimated nearly half of dementia cases could theoretically be prevented by addressing 14 modifiable risk factors across a person’s life, one of which is elevated low-density lipoprotein, or LDL, cholesterol from midlife onward. Ternhamar noted that this factor could matter especially for people with type 2 diabetes, since high LDL is common in that group and diabetes itself is separately recognized as a risk factor for cognitive decline. Detecting and treating high LDL from midlife, he said, is one of the more actionable levers available, since cholesterol-lowering drugs are already a routine, low-cost part of managing type 2 diabetes for cardiovascular reasons alone.

Statins Are Considered Underused Despite Established Heart Benefits

Ternhamar argued the results point to a missed opportunity in current practice. “Statins seem to be underused in patients with type 2 diabetes, despite their protective effects against cardiovascular disease,” he said, adding that the findings suggest “another potentially important reason to ensure that patients with type 2 diabetes and high LDL-C receive timely statin treatment.” Professor Isabel Goncalves, a member of the ESC Communication Committee who was not involved in the research, said the study builds on the fact that people with type 2 diabetes already face a higher dementia risk and are routinely advised to lower cholesterol to protect their hearts. She called the possible added benefit for dementia risk “modest” but noteworthy given how accessible statins already are.

An Observational Study Cannot Prove Statins Prevent Dementia

Both Ternhamar and Goncalves were explicit that the study cannot establish cause and effect. It is observational, meaning statin users and non-users may have differed in other health habits, medical monitoring or access to care that were not fully captured by the statistical adjustments. Goncalves said the results “should therefore support further research and help inform discussions between patients and clinicians,” rather than stand as dietary or medical advice on their own. A relative risk reduction of 15% also needs to be read against the modest absolute rate of dementia recorded in the study: 2.7% of the full population developed the condition over the follow-up period, so the difference between groups reflects a shift in that already small baseline rather than a guarantee for any individual. Only a randomized trial designed specifically to test statins against dementia outcomes could confirm whether the drugs are truly protective, something the authors say their registry data cannot deliver on its own. For now, the researchers frame the results as a talking point for medical appointments rather than a reason for people to start or stop any medication on their own, since decisions about statin timing and dosage depend on a person’s full cardiovascular and metabolic profile, not on a single population-level study.

This article was produced with the assistance of AI and reviewed by Morning Overview editors prior to publication.

More from Morning Overview